Cargando…

Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors

BACKGROUND: Older adults aged 65 years and above remain underrepresented in cancer clinical trials. We hypothesized that older participation in early phase trials with VEGF/VEGFR (VEGF/R) inhibitors was lower than cancer prevalence in this group and lower than other age groups (middle age, adolescen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subbiah, Ishwaria M., Tang, Chad, Rao, Arvind, Falchook, Gerald S., Subbiah, Vivek, Tsimberidou, Apostolia M., Karp, Daniel, Kurzrock, Razelle, Hong, David S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034739/ https://www.ncbi.nlm.nih.gov/pubmed/29989021 http://dx.doi.org/10.18632/oncotarget.25571

Ejemplares similares

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2015)

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience
por: Corrales-Medina, Fernando F., et al.
Publicado: (2014)

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
por: Falchook, Gerald S., et al.
Publicado: (2013)

Dataset of phase I and II immunotherapy clinical trials used for a meta-analysis to assess the role of biomarkers in treatment outcomes in diverse cancers
por: Fountzilas, Elena, et al.
Publicado: (2023)

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
por: Reilley, Matthew J., et al.
Publicado: (2017)

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2013)

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials
por: Said, Rabih, et al.
Publicado: (2014)

Clinical trial design in the era of precision medicine
por: Fountzilas, Elena, et al.
Publicado: (2022)

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
por: Sen, Shiraj, et al.
Publicado: (2018)

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses
por: Wheler, Jennifer, et al.
Publicado: (2013)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials
por: Livingston, J. Andrew, et al.
Publicado: (2016)

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
por: Sen, Shiraj, et al.
Publicado: (2018)

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
por: El-Osta, Hazem, et al.
Publicado: (2011)

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
por: Goldstein, Jennifer B., et al.
Publicado: (2017)

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience
por: Hou, Ming-Mo, et al.
Publicado: (2014)

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
por: Park, Haeseong, et al.
Publicado: (2016)

DCVax®- DIRECT: autologous activated dendritic cells for image guided intra-tumoral vaccination in patients with solid tumors - a phase I/II clinical trial in progress
por: Subbiah, Vivek, et al.
Publicado: (2013)

Exclusion of Older Adults in COVID-19 Clinical Trials
por: Abi Jaoude, Joseph, et al.
Publicado: (2020)

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
por: Jimenez, Camilo, et al.
Publicado: (2020)

Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape
por: Subbiah, Ishwaria M., et al.
Publicado: (2017)

Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers
por: Adashek, Jacob J, et al.
Publicado: (2020)

Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials
por: Lin, Timothy A., et al.
Publicado: (2020)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
por: Fu, Siqing, et al.
Publicado: (2015)

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy
por: Tsimberidou, Apostolia M, et al.
Publicado: (2015)

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
por: Wang, Yudong, et al.
Publicado: (2018)

Phases I–III Clinical Trials Using Adult Stem Cells
por: Gimble, Jeffrey M., et al.
Publicado: (2011)

Phases I–III Clinical Trials Using Adult Stem Cells
por: Sanz-Ruiz, Ricardo, et al.
Publicado: (2010)

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
por: Naing, Aung, et al.
Publicado: (2013)

Phase I Cancer Clinical Trials
por: Ledermann, J A
Publicado: (2007)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015)

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018)

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
por: Wang, Yudong, et al.
Publicado: (2020)

Clinical Trial Availability by Location for 1000 Simulated AYA Patients
por: McLeod, Katie L., et al.
Publicado: (2022)

The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China
por: Xiao, Jinyan, et al.
Publicado: (2022)

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
por: Mendoza, Tito R., et al.
Publicado: (2022)

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
por: Said, Rabih, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hl46p84abji20elsdn74bkqgg6